Chemical | 12 June 2021
India aims to vaccinate 1 crore people every day
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company reported total income of Rs.837.32 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.13.71 crores for the 12 months period ended March 31, 2021
The stable outlook reflects Moody's view that TCL will sustain revenue growth across all its businesses
The said patent also covers the fungicidal composition, Hexaconazole 4% + Carbendazim 16% SC which the company has been selling pan-India under the Trademark of “SOFIA”
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
ReProSolar offers an innovative management of PV modules, turning the linear PV industry into a circular economy in order to reduce waste and to protect valuable resources
The date of the business transfer is scheduled for end of June 2021
The company reported net sales of Rs.103.89 crores during the 6 months period ended March 31, 2021
The company reported total income of Rs.107.96 crores during the 12 months period ended March 31, 2021
The total Capex planned for doubling chemicals and tripling fertilizers capacities is Rs. 120 - 130 crore and it is 100% funded through internal accruals.
Dudick, headquartered in Streetsboro, Ohio, has annual net sales of approximately US $10 million
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Fluindapyr provides broad-spectrum activity against a wide range of destructive diseases in row and specialty crops, as well as turf
The multi-million dollar expansion will help the company meet growing demand for its new product line
Company will work together with Stanford University scientists to scale up the synthesis and formulation, and further develop this innovative technology for organ selective delivery based on a non-animal-derived, synthetic degradable polymer
Together with the shares it previously acquired, PPG now controls 97.1% of Tikkurila’s issued and outstanding shares
Near to medium term growth would remain under pressure due to slow recovery in radiopharma business
Company has established strong levers of growth to deliver superior performance over the medium term.
Subscribe to our newsletter & stay updated.
_195_291.jpg)
